Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ lowered its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 29.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 89,047 shares of the company’s stock after selling 37,035 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned 0.31% of Krystal Biotech worth $14,230,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. Entropy Technologies LP purchased a new stake in shares of Krystal Biotech during the 4th quarter worth approximately $548,000. Summit Trail Advisors LLC purchased a new stake in Krystal Biotech during the third quarter worth $1,893,000. Swiss National Bank boosted its position in Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company’s stock worth $7,117,000 after purchasing an additional 2,900 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in Krystal Biotech by 42.0% during the fourth quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company’s stock worth $8,239,000 after purchasing an additional 15,545 shares in the last quarter. Finally, Citigroup Inc. boosted its position in Krystal Biotech by 65.4% during the third quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock worth $6,386,000 after purchasing an additional 13,874 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Stock Performance

Shares of KRYS opened at $179.38 on Friday. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34. The company has a market capitalization of $5.17 billion, a price-to-earnings ratio of 59.99 and a beta of 0.87. The company’s 50 day simple moving average is $163.50 and its 200 day simple moving average is $174.07.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same quarter in the prior year, the company posted $0.30 EPS. The business’s revenue for the quarter was up 116.4% compared to the same quarter last year. Equities analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Chardan Capital upped their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday, February 20th. Citigroup upped their target price on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. Finally, Jefferies Financial Group initiated coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 target price on the stock. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $220.00.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).